COVID-19-Related Stroke: Barking up the Wrong Tree?

Dear Editor, We are grateful to Hooshmandi et al. [1] (ENE-20204-59) for the interest shown in our article and for their comments. At the time of writing, Piacenza was the second most heavily hit Italian city by COVID-19 pandemic (1.415%) [2], providing an exceptional perspective of the current situation in the neurological field. We previously emphasized how the main limit of our comments was the brief observation period, that is, 1 month, that is when the outbreak of SARS-CoV-2 peaked. In the following period, only few small case series of COVID-19 stroke patients have been reported [3–8]. Therefore, little information is available on stroke in this unknown pathological scenario. Despite the lack of current scientific literature on the topic, which is limited to anecdotal reports, numerous hypotheses have been put forward as to the role of the thrombophilic state induced by 2019-nCoV and the likely increased risk of stroke in infected patients [9–11]. From February 21 to April 28, 2020, 854 COVID-19 patients were admitted to our facility, 17 of whom with concomitant ischemic stroke symptoms (mean age 76.1 ± 8.8). No young adult stroke patient was observed. There was no rare stroke etiology or unforeseen high incidence in stroke subtypes. Severity of stroke evaluated by the NIHSS seems to correlate with extension of interstitial pneumonia documented with chest CT scan (personal data, in press). However, anecdotal evidence is collected in a casual or informal manner and relies entirely on personal testimony. Therefore, it is generally considered to have a limited value, due to a number of potential weaknesses. For this reason, we agree with Hooshmandi et al. that it is too early to consider a direct “cause-effect” relationship between 2019-nCoV infection and stroke occurrence so that further prospective and large-volume studies are warranted. The occurrence of different types of cerebrovascular diseases during the 2019-nCoV pandemic can be documented only by international multicenter studies. Indeed, the prevalence of COVID-19 is so high in pandemic hotspots that an incidental association between infection and neurological manifestations cannot be excluded. During a pandemic, when science and medicine are asked to provide answers, neurologists should strive to keep high scientific research standards and place trust in their clinical methods, starting with an accurate patient interview and then moving through standard neurological examination. The clinical path is then completed by